Analysis of oral cancer specific biomarkers as a validation tool for future diagnosis

Abstract

M Athar* and S Malviya

Biomarkers are widely delegated to the genome, proteomics, or metabolomics. Nuclear science and oncology studies include cancer amelioration, risk assessment, screening, prognosis of recurrence, proof of suspicion, indication of aggression/metastasis, and review of the healing response of cancer biomarkers that are widely delegated to the genome. Focusing on oral cancer biomarkers, proteomics, or metabolomimic, focusing on the identification of relevant important natural particles or markers. Subatomic science and oncology studies focus on oral cancer biomarkers for cancer improvement, risk assessment, screening, recurrence prediction, suspicion, invasion/metastasis detection, and cancer recovery response. The focus is on the detection of important natural atoms or markers involved in the review. The bundle of segregating factors 34 is a salivary biomarker that can distinguish recidivism from Oral Squalors Cell Carcinoma (OSCC). Integrin α3 and integrin β4 are genomic biomarkers that help assess the game of dangerous oral squamous epithelial cell territory and hematogenous spread. Various models are vascular endothelial development factors, B-cell lymphoma 2, claudin 4, ye-related proteins 1, MET proto-oncogenes and receptor tyrosine kinases, and genomes used to predict radiation resistance in OSCC tissues. It is a biomarker.